SEC Tracker
Get the app

Ovid Therapeutics OVID

Ovid Therapeutics reports Q3 2026 financial results

Ovid Therapeutics (OVID) filed an 8-K with the SEC on Nov 10, 2026, 7:03 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents and marketable securities were $161.4 million as of September 30, 2026
  2. OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027
  3. Ovid plans to initiate a study in TSC-associated seizures before year-end 2026
  4. OV4071, the first-ever oral KCC2 direct activator, continues to progress in a Phase 1 study

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Ovid Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.